Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy-induced thrombosis: a role for microparticles and tissue factor?

Literature DB >> 18645926

Chemotherapy-induced thrombosis: a role for microparticles and tissue factor?

Abstract

Chemotherapy is an independent risk factor of thromboembolic events in cancer patients. Various pathogenetic mechanisms have been hypothesized in the past, but until now their individual contribution to the risk of thrombosis has been hardly investigated in clinical trials. In recent years, studies increasingly suggested an association between the prothrombotic state in cancer patients and circulating tissue factor-exposing microparticles. In this review, we discuss the roles of tissue factor and microparticles with regard to chemotherapy-induced hypercoagulability.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18645926 DOI： 10.1055/s-2008-1079261

Source DB: PubMed Journal: Semin Thromb Hemost ISSN： 0094-6176 Impact factor: 4.180

Keyword Cloud
Cited

10 in total

1. Differential biomarker profiles between unprovoked venous thromboembolism and cancer.

Authors: V Sánchez-López; L Gao; M Ferrer-Galván; E Arellano-Orden; T Elías-Hernández; L Jara-Palomares; M I Asensio-Cruz; M J Castro-Pérez; F J Rodríguez-Martorell; J L Lobo-Beristain; A Ballaz-Quincoces; J L López-Campos; V Vila-Liante; R Otero-Candelera
Journal: Ann Med Date: 2020-07-15 Impact factor: 4.709

2. Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.

Authors: Eric T Alexander; Allyson R Minton; Candace S Hayes; Ashley Goss; Joanne Van Ryn; Susan K Gilmour
Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742

3. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.

Authors: Mourad Chaari; Ines Ayadi; Aurelie Rousseau; Eleftheria Lefkou; Patrick Van Dreden; Fatoumata Sidibe; Hela Ketatni; Vassiliki Galea; Amir Khaterchi; Racem Bouzguenda; Mounir Frikha; Lilia Ghorbal; Jamel Daoud; Choumous Kallel; Martin Quinn; Joseph Gligorov; Jean Pierre Lotz; Mohamed Hatmi; Ismail Elalamy; Grigoris T Gerotziafas
Journal: BMC Cancer Date: 2014-12-22 Impact factor: 4.430

4. A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.

Authors: Pavani Chalasani; Marilyn Marron; Denise Roe; Kathryn Clarke; Maria Iannone; Robert B Livingston; Joseph S Shan; Alison T Stopeck
Journal: Cancer Med Date: 2015-03-31 Impact factor: 4.452

5. Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.

Authors: Eric T Alexander; Allyson R Minton; Molly C Peters; Joanne van Ryn; Susan K Gilmour
Journal: Oncotarget Date: 2016-12-20

Chemotherapy-induced thrombosis: a role for microparticles and tissue factor?

1. Differential biomarker profiles between unprovoked venous thromboembolism and cancer.

2. Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.

3. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.

4. A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.

5. Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.

Review 6. Tumor-Derived Apoptotic Vesicles: With Death They Do Part.

Review 7. Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy.

8. Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy.

9. Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles.

10. Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management.